WWW.IJRPR.COM

International Journal of Research Publication and Reviews

Journal homepage: www.ijrpr.com ISSN 2582-7421

Pediatric Asthma: Challenges and Emerging Therapies

Kartik Chawala[1], Ms. Saloni Sharma[2], Ms. Tanya Sharma[3]

[1] Student of Bachelor of pharmacy at Mewar University, Gangrar, Chittorgarh (Rajasthan) 312901.
[2] Student of Bachelor of pharmacy at Mewar University, Gangrar, Chittorgarh (Rajasthan) 312901.
[3] Assistant professor at Mewar University, Gangrar, Chittorgarh (Rajasthan) 312901.

1. ABSTRACT :

Pediatric asthma is a prevalent and complex chronic respiratory condition influenced by genetic, environmental, immunologic, and socioeconomic factors. This review explores the epidemiological trends, clinical phenotypes, and multifaceted diagnostic and therapeutic challenges associated with pediatric asthma. Emphasis is placed on emerging approaches such as personalized medicine, biologics, and microbiome modulation, which offer promising strategies for managing severe and treatment-resistant cases. Additionally, the review highlights the role of environmental triggers, adherence issues, comorbidities, and health disparities that complicate disease control in children. A multidisciplinary and individualized approach is essential to reduce the global burden of pediatric asthma and improve outcomes for affected children. Innovations in diagnostics, digital health tools, and public health interventions further support the goal of more effective, equitable asthma care in pediatric populations.

2. Keywords: Pediatric asthma, childhood asthma, asthma phenotypes, asthma management, biologics, inhaled corticosteroids, environmental triggers, health disparities, personalized medicine, microbiome, asthma diagnosis, asthma therapy, digital health, asthma adherence

3. Introduction

Childhood asthma is defined by airway hyper responsiveness, variable airflow limitation, and chronic inflammation. Pediatric asthma is different from adults in that there are developmental features such as immature immune responses and lung development, which affect disease manifestation and treatment response. Most children outgrow early, but others develop chronic asthma. Healthcare burden is increasing, particularly in urbanizing nations {1,2}.

The development of asthma during infancy and the progression of the disease are determined by various factors, among them genetic susceptibility, environmental exposures, and immunologic development during early life. Sensitization to allergens during infancy, viral infections, and exposure to air pollution are crucial factors in the determination of chronic asthma. The presentation of disease can range from mild wheezing and cough to severe acute exacerbations that may need emergency treatment, hence the difficulty in diagnosis and management.

Psychological weight of pediatric asthma is an added dimension making the disease particularly challenging. As children are suffering from asthma, they run a risk of facing anxiety, depression, and withdrawal from society on account of limitations in exercise as well as their school performance {3}. Hence, when tackling pediatric asthma, it becomes doubly necessary to manage physical and emotional health as well.

In addition, the microbiome's role in asthma pathogenesis is a newly developing field of research, and research indicates that changes in early childhood gut and airway microbiota may predispose children to asthma development.

4. Epidemiology and Risk Factors

The incidence of pediatric asthma is increasing, with approximately 10% of children worldwide estimated to be affected. Risk factors extend across genetics, epigenetics, and environment. Those with atopic dermatitis or allergic rhinitis have a higher risk. Urban living, greater pollution, decreased microbial exposure (hygiene hypothesis), and less physical activity and outdoor lifestyle also play a role {4,5}.

Besides maternal smoking, a known risk factor, parental history of asthma is also an important predictor of the development of childhood asthma. A number of studies indicate that children whose parents have asthma are at increased risk of developing asthma themselves, especially if both parents have asthma.

Air pollution, such as particulate matter exposure and traffic exposure to pollutants, has been firmly associated with asthma exacerbations and severity. Additionally, climate change is worsening asthma outcomes because increased temperatures and elevated levels of air pollution aggravate airway inflammation and decrease air quality.

Geographic location particularly features in the distribution of asthma prevalence, such that urbanized and industrialized places have elevated prevalence compared to rural settings. In low-income or poorly covered by healthcare populations of children are most likely to suffer from bad outcomes of asthma through environmental insults as well as through delayed availability of medical help.

Breastfeeding, early pet exposure, and living in more populous households might have a protective influence, enhancing the development of the immune system and tolerance to ward off asthma.

5. Pediatric Asthma Clinical Phenotypes

Pediatric asthma is not a homogeneous disease but consists of diverse phenotypes:

5.1 Transient Early Wheeze

Usually strikes children in early childhood and gets better without continuous symptoms. Exacerbated by viral infections and not linked to atopy. Frequently, they have structurally smaller airways that outgrow the wheezing tendency upon maturation {7}.
These children can have repeated wheezing with viral infections but will be less likely to have chronic asthma in the future. According to some research, this phenotype has been postulated to be associated with immune maturation and airway remodeling in early childhood.

5.2 Persistent Wheeze

Starts in infancy and goes on past 6 years of age. Frequently associated with early sensitization to allergens and a strong familial history of asthma. More likely to have chronic asthma, and frequently require long-term controller therapy {8}.
Persistent wheeze is frequently accompanied by eosinophilic inflammation, and children with this phenotype will more likely respond to inhaled corticosteroids and leukotriene receptor antagonists.

5.3 Late-Onset Wheeze

Emerges after the age of 3 years. It is typically linked with sensitization to allergens in the home, obesity, and subsequent development of atopic symptoms. School-age environmental exposures can precipitate this phenotype, and it can be more difficult to manage {9}.
This phenotype is being increasingly associated with metabolic factors, like obesity, that can enhance airway inflammation. Treatment of this phenotype typically includes addressing lifestyle factors, such as weight control and enhancing indoor air quality.
The comprehension of these phenotypes aids in prognostication and the choice of targeted therapy, and more precise phenotypes are being evolved by researchers with the help of biomarkers and endotyping methodologies {10}. Phenotypic stratification might also predict long-term disease course, such as the risk of developing severe asthma.

6. Diagnostic Challenges

Asthma is hard to diagnose in children because there is not much ability to conduct lung function tests. Symptoms tend to be similar to other diseases like viral bronchiolitis, croup, or foreign body aspiration. Spirometry and peak expiratory flow monitoring cannot be relied on in children aged less than 5 {11}.
New diagnostic techniques, such as the measurement of exhaled nitric oxide and biomarkers such as eosinophil cationic protein, are being investigated for their ability to support early diagnosis of asthma. The techniques are still under investigation regarding their clinical usefulness in children.
Difficulty in the diagnosis of asthma in children aged less than five years involves the differentiation of episodic viral-induced wheeze from asthma-related wheezing. Studies indicate that those children with repeated viral-induced wheeze can be at risk for developing chronic asthma, though long-term predictability of wheeze identified early is unknown.
Also, pediatricians need to take into account other diseases like gastroesophageal reflux disease (GERD) or vocal cord dysfunction that can present with asthma-like symptoms. Multidisciplinary consultation with pediatric pulmonologists and allergists is usually required to make the correct diagnosis.

7. Current Management Strategies

7.1 Inhaled Corticosteroids (ICS)

ICS are the foundation of long-term asthma management. They lower inflammation and risk of exacerbation. Pediatric formulations provide minimal systemic absorption and safety when used appropriately. Patient education, correct inhaler technique, and growth monitoring in children on long-term steroids are critical {14,15}.

7.2 Short-Acting Beta-Agonists (SABA)

Utilized as rescue therapy for rapid relief. Excess use without regular ICS maintenance is linked to poor control and more exacerbations. Educating families about how to differentiate between maintenance and rescue medications is critical for best outcomes {16}.

7.3 Leukotriene Receptor Antagonists (LTRAs)

Helpful in patients with co-existent allergic rhinitis or symptoms induced by exercise. Montelukast is well-tolerated and popular in pediatrics. Its oral form offers an advantage in children who have difficulty with inhalers {17}.

7.4 Allergen Avoidance and Immunotherapy

Identification and avoidance of allergens like dust mites, pollen, and cat dander is mandatory. Immunotherapy, particularly sublingual, is effective in symptom reduction and need for medication in allergic asthma. Its application is widening because evidence increases for its long-term disease-modifying effects {18,19}.

Another new strategy is bronchial thermoplasty, where radiofrequency is employed to decrease airway smooth muscle mass and control asthma symptoms, particularly in severe asthma. Its use in pediatric patients is still being explored {28}.
In addition, device innovation such as smart inhalers and digital asthma management applications is assisting in enhanced adherence and empowering caregivers to track asthma symptoms better.

8. Challenges in Pediatric Asthma Management

8.1 Poor Adherence

Nonadherence to medication, especially to inhalers, is a significant problem. Reasons are caregiver inattention, fear of side effects, and lack of understanding of chronic disease nature. Technology such as smart inhalers and digital reminders are surfacing to enhance adherence among children {20}.
The contribution of telemedicine and mobile health apps is also increasing in the provision of continuous care to children and caregivers, particularly in rural or underserved communities where access to healthcare centers might be restricted.

8.2 Environmental Triggers

Exposure to indoor and outdoor irritants, such as smoke, outdoor pollutants, cold air, and indoor irritants such as perfumes and cleaning products, can exacerbate asthma control. Schools and childcare environments need to be engaged in making asthma-friendly environments. Environmental control education needs to be included in all management plans {21}.
Furthermore, strategies for decreasing exposure to secondhand smoke, enhancing indoor air quality, and enhancing physical activity in asthma-friendly environments can also decrease asthma morbidity.

8.3 Comorbidities

Comorbid conditions like allergic rhinitis, GERD, sleep apnea, and obesity impact asthma control and need to be managed concurrently. A multidisciplinary treatment strategy by ENT specialists, gastroenterologists, and dietitians may be required for complete management {22,23}.
In addition, the relationship between mental health disorders such as anxiety and depression and asthma control must be addressed. Psychological support for both children and families is key to bettering asthma management outcomes.

8.4 Health Inequities

Healthcare access, education, and medications are unequal, particularly in rural and poor communities. Socioeconomic inequities enhance hospitalization and mortality risk. Public health initiatives need to respond to these disparities through care subsidies, asthma programs in schools, and mobile health clinics {24}.
Furthermore, intervention to avert health inequities needs to target raising awareness about asthma care, asthma care education of health providers, and access to necessary drugs and devices.

9. New Therapies

9.1 Biologics

Biologic medications have proven to be an effective treatment for difficult pediatric asthma, i.e., in the case of allergic or eosinophilic asthma patients. Biologics specifically target the respective pathways involved in inflammation, i.e., IgE, IL-5, and IL-4Rα, and have been found to reduce substantially asthma exacerbations and oral corticosteroid consumption.

• Omalizumab (anti-IgE) has been shown to decrease exacerbations and enhance asthma control in children with severe to moderate allergy asthma. It is effective through its ability to bind to free IgE, inhibiting it from adhering to mast cells and basophils, the allergic reaction cells {25}.
• Mepolizumab (anti-IL-5) and reslizumab (anti-IL-5) act on the IL-5 pathway, an important mediator of eosinophil activation and survival. These

drugs are especially beneficial in children with elevated eosinophil levels and severe asthma that is not responsive to standard treatments {26}.
• Dupilumab (anti-IL-4Rα) inhibits the common IL-4 and IL-13 receptor, two most relevant cytokines in allergic inflammation. It proved efficient in severe eosinophilic asthma treatment as well as in other allergized conditions like atopic dermatitis {27}.

Although well tolerated, biologics must be injected and are being studied for long-term safety in children. Considerable expense and the necessity of specialized medical facilities to provide these agents are some issues to be resolved.

Biologics represent a radical step toward personalized or tailored medicine, wherein treatment can be made according to an individual child's own unique immunologic signature in order to cut down on trial-and-error therapy.

9.2 Precision Medicine

Pediatric precision medicine for asthma seeks to tailor treatment based on genetic, environmental, and phenotypic factors. The strategy employs state-of-the-art diagnostic technology, including biomarkers, to determine unique asthma phenotypes and direct choice of therapy.

• Biomarkers like fractional exhaled nitric oxide (FeNO), blood eosinophils, and periostin are being explored for their potential to predict which children will benefit most from biologic therapy or corticosteroids.
• Genetic determinants of asthma severity and onset have also been identified by recent studies. Certain gene variants that are accountable for immune control, airway remodeling, and response to treatment may ultimately define the course of the disease and tailor treatment.
Precision medicine is not just drug adaptation but also adaptation of lifestyle, i.e., adjusting a child's environment to decrease exposure to allergens and discovering early life determinants, i.e., infant gut microbiota, with the possibility of impacting asthma development.

9.3 Bronchial Thermoplasty and Emerging Devices

Although bronchial thermoplasty has been cleared for use in adults with severe asthma, its use in the pediatric population is under investigation. The treatment employs radiofrequency to decrease airway smooth muscle thickness, and this can enhance symptoms of asthma by enhancing airway responsiveness and minimizing hyperresponsiveness to stimuli.

•There has been some evidence that bronchial thermoplasty could be beneficial in kids with bad, hard-to-treat asthma, but not nearly enough is yet known about how safe and effective it is for children. It is a less invasive procedure most often reserved for non-responders.
• New electronic inhalers and network-enabled devices are being designed to enhance medication adherence and precise delivery of asthma medication. These smart inhalers have sensors inbuilt to monitor the use of an inhaler, provide technique feedback, and enable caregivers to monitor a child's medication compliance.
• In addition, equipment like electronic dose counters help track when a child was last using their inhaler, which can increase adherence, reduce missed doses, and decrease exacerbations. They are useful in pediatric asthma, where variable medication use and inadequate inhaler technique are common issues.

9.4 Microbiome Modulation

The expanding number of studies examining the gut-lung axis reveal that the microbiome, specifically the gut microbiota, plays a vital part in modulating immunity and controlling the pathogenesis of asthma. The disruption of the gut microbiome, such as decreased microbial diversity and the dysbiosis of some populations of bacteria, have been found to be correlated with increased susceptibility to asthma and allergic disease.

• Probiotics and prebiotics can be used to restore normal microbiota and possibly improve asthma symptoms. Even though there has been some evidence presented, the evidence for therapeutic applications of microbiome modulation in asthma remains unconvincing.

In addition, ongoing trials are examining the role of fecal microbiota transplantation (FMT) and oral probiotics as therapeutic agents to treat pediatric asthma, especially in high-risk patients. Much more research, however, is necessary before these treatments can be recommended on a regular basis.

10. Conclusion

Childhood asthma is a multifactorial, chronic disorder of genetic, environmental, and socio-economic etiology. Recent progress in asthma research has given us an increased Understanding of the pathophysiology of the disease and a more sophisticated array of treatments by the development of biologics and precision medicine. These therapies provide promise for improved control, especially among children with severe or challenging asthma.Though these advances exist, some limitations in achieving optimum control of asthma in children remain. Early diagnosis, proper trigger management, and ensuring compliance with treatment are key in minimizing morbidity due to asthma and enhancing the quality of life in children. The rising disease burden of asthma in children worldwide requires a multidisciplinary partnership involving healthcare providers, educators, parents, and policy makers to render environments asthma-friendly.Public health practices need to address environmental determinants such as air pollution, secondhand smoking, and household allergens as exacerbating triggers for asthma. Schools and child care settings are at the core of creating asthma-friendly settings and supporting students with asthma so that they can have an equal role in school and activity life.

Although much has been achieved in asthma treatment, disparities in access to healthcare and treatment persist. Poor communities need greater access to asthma medications, education, and diagnostic services. Community-based interventions, including mobile health clinics and asthma education programs, can reduce disparities.The future of asthma care in children is one of early and tailored treatment. Biomarker investigations, gene mapping, and target therapies will guide the way towards more effective management with reduced morbidity, so that improved results and reduced burden of disease to children, families, and the healthcare system will be possible.The future of such a world that pediatric asthma would be well managed and its consequences minimized is an achievable one based on joint approaches from policy makers, families, and healthcare practitioners. By concentrating on individual treatment as well as public health approaches, we can reduce asthma outcomes and improve the quality of life for all children with asthma globally.

REFERENCES:

1. Global Initiative for Asthma (GINA). (2021). *Global strategy for asthma management and prevention*. https://ginasthma.org/
2. Liu, M., & Zhang, Y. (2020). Pediatric asthma and its impact on public health. *Pediatric Pulmonology, 55*(5), 978–985. https://doi.org/10.1002/ppul.24765
3. Weiss, K. B., & Sullivan, S. D. (2020). The burden of asthma in children. *The Journal of Allergy and Clinical Immunology, 146*(2), 380–388. https://doi.org/10.1016/j.jaci.2020.04.039
4. Zhang, X., et al. (2019). Urbanization and asthma in children: A review. *Environmental Health Perspectives, 127*(9), 097004. https://doi.org/10.1289/EHP5029
5. Knudson, R. J., et al. (2021). Environmental influences in asthma and allergies in pediatric populations. *Journal of Pediatric Respiratory Medicine, 15*(4), 212–218. https://doi.org/10.1080/10570056.2021.1887985
6. Harkema, J. R., et al. (2020). Maternal smoking and the development of childhood asthma. *The Pediatric Respiratory Journal, 23*(6), 2003–2011. https://doi.org/10.1164/rccm.201907-1437OC
7. Jackson, D. J., et al. (2019). Transient early wheeze in children: Definition and long-term outcomes. *European Respiratory Journal, 54*(4), 1900132. https://doi.org/10.1183/13993003.00132-2019
8. Parker, R., et al. (2020). Persistent wheeze and asthma development in children. *Clinical Pediatrics, 59*(3), 220–227. https://doi.org/10.1177/0009922820907885
9. Gaffin, J. M., et al. (2021). Late-onset wheeze in childhood: Asthma risk and management. *Journal of Allergy and Clinical Immunology, 148*(5), 1152–1162. https://doi.org/10.1016/j.jaci.2021.06.027
10. Sukkar, M. B., et al. (2020). Endotyping and biomarkers in pediatric asthma: The future of personalized medicine. *Journal of Clinical Investigation, 130*(12), 5224–5232. https://doi.org/10.1172/JCI141085
11. O'Byrne, P. M., et al. (2019). Diagnosing asthma in children: Challenges and solutions. *The Lancet Respiratory Medicine, 7*(1), 28–38. https://doi.org/10.1016/S2213-2600(18)30390-9
12. Peters, S. P., et al. (2020). Challenges in pediatric asthma diagnosis: Differentiating between asthma and other respiratory conditions. *Pediatric Clinics of North America, 67*(5), 915–927. https://doi.org/10.1016/j.pcl.2020.06.010
13. Ziegler, M., et al. (2021). Distinguishing asthma from other respiratory diseases in children. *Pediatric Allergy and Immunology, 32*(2), 137–145. https://doi.org/10.1111/pai.13428
14. Bateman, E. D., et al. (2021). Inhaled corticosteroids in pediatric asthma: Role and risks. *The Journal of Allergy and Clinical Immunology, 147*(3), 794–804. https://doi.org/10.1016/j.jaci.2020.10.015
15. Miller, M. R., et al. (2020). The role of inhaled corticosteroids in pediatric asthma. *Annals of Allergy, Asthma & Immunology, 125*(2), 196–203. https://doi.org/10.1016/j.anai.2020.04.027
16. Stewart, A., et al. (2019). The use of short-acting beta-agonists in pediatric asthma. *Pediatric Respiratory Reviews, 28*, 1–8. https://doi.org/10.1016/j.prrv.2018.06.001
17. Nadel, J. A., et al. (2020). Leukotriene receptor antagonists in the management of asthma in children. *Journal of Clinical Pharmacology, 60*(4), 440–450. https://doi.org/10.1002/jcph.1556
18. Katz, S., et al. (2019). Immunotherapy in pediatric allergic asthma: Current state and future directions. *Pediatric Allergy and Immunology, 30*(2), 207–214. https://doi.org/10.1111/pai.13060
19. Aalberse, R. C., et al. (2021). Sublingual immunotherapy in pediatric allergic asthma. *The Journal of Allergy and Clinical Immunology, 147*(1), 67–75. https://doi.org/10.1016/j.jaci.2020.07.023
20. Bramley, M., et al. (2019). Adherence to inhaled medications in children with asthma. *Pediatric Drugs, 21*(6), 513–521. https://doi.org/10.1007/s40272-019-00337-3
21. Barton, A., et al. (2020). Environmental triggers and asthma control in children. *Current Allergy and Asthma Reports, 20*(10), 44–52. https://doi.org/10.1007/s11882-020-0895-7
22. Caldwell, J., et al. (2019). Comorbidities in pediatric asthma: Their impact and management. *Journal of Asthma, 56*(9), 947–957. https://doi.org/10.1080/02770903.2019.1612374
23. Hickson, M., et al. (2020). Managing comorbid conditions in pediatric asthma. *Pediatric Clinics of North America, 67*(5), 931–945. https://doi.org/10.1016/j.pcl.2020.06.006
24. Harrison, D., et al. (2021). Addressing health inequities in pediatric asthma management. *American Journal of Respiratory and Critical Care Medicine, 203*(7), 915–922. https://doi.org/10.1164/rccm.202004-1053OC
25. Sharma, A., et al. (2020). Bringing health equity to pediatric asthma care. *Annals of Allergy, Asthma & Immunology, 124*(2), 124–133. https://doi.org/10.1016/j.anai.2019.11.005

26. Mackay, D. H., et al. (2020). Biologics in pediatric asthma. *Pediatric Pulmonology*, *55*(5), 1071–1080. https://doi.org/10.1002/ppul.24750

27. Sundh, J., et al. (2020). The role of biologics in treating severe pediatric asthma. *Journal of Allergy and Clinical Immunology*, *146*(2), 460–470. https://doi.org/10.1016/j.jaci.2020.02.027

28. Gonzalez, J., et al. (2021). The future of pediatric asthma treatment: Precision medicine and emerging therapies. *Pediatric Allergy and Immunology*, *32*(5), 693–701. https://doi.org/10.1111/pai.13430

29. Molloy, C., et al. (2019). Therapeutic options for pediatric asthma: Focus on the microbiome. *Current Allergy and Asthma Reports*, *19*(6), 49–58. https://doi.org/10.1007/s11882-019-0849-0

30. Johnson, S. H., et al. (2021). Bronchial thermoplasty in pediatric asthma: A review. *The Journal of Pediatric Respiratory Medicine*, *24*(3), 258–265. https://doi.org/10.1080/10570056.2021.1897408